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Scientific summary
Background
Skin cancer is one of the most common cancers in the UK. It is commonly classified into melanoma skin
cancer (or malignant melanoma), which develops from pigmented cells in the epidermis, and
non-melanoma skin cancer, which develops from cells that produce keratin. Non-melanoma skin cancer
can be further divided into squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Malignant
melanoma, SCC and BCC make up > 95% of all skin cancers.
The main risk factor for developing skin cancer is exposure to ultraviolet radiation in the form of sunlight
or from the use of sunbeds. Other factors include age, sex, ethnicity, occupation, and personal and family
history of skin cancer.
According to clinical experts, when patients with suspicious skin lesions present at secondary care, they are
first examined with a dermoscope, and those with benign lesions are discharged. However, if the results of
dermoscopy and/or the clinical features give rise to concern, the lesions are surgically excised. Therefore,
the importance of identifying truly positive lesions while curtailing the number of unnecessary biopsies
cannot be overemphasised.
The VivaScope® imaging system is a non-invasive reflectance confocal microscopy (RCM) technology that is
designed to capture highly magnified images. It is used in conjunction with dermoscopy to provide more
accurate diagnosis, leading to fewer biopsies of benign lesions and earlier detection of skin cancers. It may
also be used as a guide to surgery to provide more accurate presurgical margins, preventing unnecessarily
large scars for skin cancers in anatomical areas where tissue preservation is of importance (e.g. face,
hands, feet and genitals), and reducing the risk of recurrence.
Objectives
The following questions are addressed in the clinical effectiveness section of the diagnostic
assessment report:
l What is the clinical effectiveness and cost-effectiveness of the VivaScope® 1500 (Caliber Imaging and
Diagnostics, Rochester, NY, USA; Lucid Inc., Rochester, NY, USA; or Lucid Inc., MAVIG GmbH, Munich,
Germany) and VivaScope® 3000 (Caliber Imaging and Diagnostics, Rochester, NY, USA) in diagnosing
suspicious skin lesions?
l What is the clinical effectiveness and cost-effectiveness of VivaScope 3000 in defining the margins of
dermoscopically equivocal skin lesions?
Although this report is mainly aimed at the current versions of VivaScope (1500 and 3000), VivaScope®
1000 (Lucid Inc., Rochester, NY, USA, or Lucid Inc., MAVIG GmbH, Munich, Germany) and 2500 (Caliber
Imaging and Diagnostics, Rochester, NY, USA), which are earlier models of VivaScope 1500 and 3000,
respectively, were also considered, as they may provide additional information on the current versions.
The eligible reference standard for the assessment of diagnostic accuracy and margin delineation was
histopathology of the biopsy of the excised skin lesion.
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Methods
This assessment comprises a systematic review of clinical effectiveness and cost-effectiveness studies,
and the development of three de novo economic models.
Clinical effectiveness systematic review
Evidence for the clinical effectiveness of the interventions was identified by searching electronic databases
(MEDLINE, EMBASE, and The Cochrane Library) from inception to 14 October 2014 and updated on
11 February 2015. The search strategy combined terms capturing the interventions and comparators of
interest, and the target condition.
Randomised controlled trials and observational studies evaluating VivaScope were eligible for inclusion.
Two reviewers independently screened all titles and abstracts according to the inclusion criteria. Two
reviewers extracted data from included studies using a standardised data extraction form, and the two
extractions were validated. The quality of included studies was assessed using the quality assessment of
diagnostic accuracy studies tool, according to the Cochrane handbook for diagnostic test accuracy reviews
[Diagnostic Test Accuracy Working Group. Handbook for DTA Reviews. The Cochrane Collaboration; 2013.
URL: www.srdta.cochrane.org/handbook-dta-reviews (accessed 13 January 2015)].
Review methods
Extracted data from included studies and quality assessment for each study were presented in structured
tables and as a narrative summary. Evidence on the following outcome measures was considered:
diagnostic accuracy; number of biopsies performed and repeat biopsies (lesion diagnosis only); morbidity
associated with biopsy or excision surgery; recurrence rate (lesion margin delineation only); adverse events
from biopsy including infections; and health-related quality of life (HRQoL).
Assessment of cost-effectiveness
Evidence for the cost-effectiveness of the VivaScope in the diagnostic assessment of suspected skin lesions
was identified by searching electronic databases (MEDLINE and EMBASE), from inception to October 2014.
The Health Technology Assessment database and NHS Economic Evaluation Database were also searched
for economic evaluations addressing the review question. The search strategy combined terms capturing
the interventions and comparators of interest, and the target condition.
In addition, a de novo economic model was constructed in Microsoft Excel® 2010 (Microsoft Corporation,
Redmond, WA, USA) to estimate the cost-effectiveness of VivaScope 1500 and 3000 in lesion diagnosis
and margin delineation. According to the study populations that were identified as most relevant for the
economic evaluation of VivaScope, three separate ‘part’ economic models were developed:
1. use of VivaScope in the diagnosis of equivocal lesions suspicious of melanoma
2. use of VivaScope in the diagnosis of suspected BCC lesions following a positive or equivocal finding
on dermoscopy
3. use of VivaScope for the margin delineation of lentigo maligna (LM) prior to surgical therapy.
The analysis adopted the perspective of the NHS and Personal Social Services. Costs consisted of
intervention costs of VivaScope (including purchase and maintenance costs, costs of parts and
consumables, staff training and staff time required for the examination), costs associated with the
comparators of the analysis (such as costs of biopsy, histological examination and monitoring), costs of
management of skin lesions following diagnosis, as well as costs incurred following the presurgical
mapping of malignant skin lesions. All costs were expressed in 2014 prices.
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The outcome measure of the economic analysis was the quality-adjusted life-year (QALY). The impact of
the intervention and its comparators on people’s HRQoL was associated with the potential distress from
excision and/or diagnostic biopsy of a lesion, the anxiety while waiting for the diagnostic results, the
unnecessary treatment of people with false-positive (FP) lesions, the progression of the disease in people
with false-negative (FN) lesions and the permanent disutility because of scarring following surgical
intervention of skin lesions on head or neck. Costs and outcomes were discounted at an annual rate
of 3.5%.
Utility data were taken from a systematic review of the literature. The company (MAVIG GmbH, Munich,
Germany) provided the costs associated with the intervention (VivaScope 1500 and 3000 imaging system),
including the purchase price of the equipment and parts and maintenance costs.
Each of the ‘part’ models consisted of a decision tree, followed by a Markov model, which followed patients
and measured future consequences (costs and outcomes) over their lifetime. Deterministic and probabilistic
analyses of all three-part models were undertaken. All input parameters were tested in one-way sensitivity
analyses; additional one-way sensitivity analyses were undertaken to estimate the impact of alternative
scenarios and model assumptions on the results. Finally, two-way sensitivity analyses were carried out to
test the impact of concurrently varying sensitivity and specificity of VivaScope in the diagnostic assessment
of eligible skin lesions suspicious of melanoma or BCC on the cost-effectiveness results.
Results
Clinical effectiveness systematic review
Sixteen studies (13 from electronic databases and three from contacting clinical experts) met the inclusion
criteria. Thirteen of the studies investigated VivaScope in diagnosing suspected or equivocal lesions, and
three studies investigated VivaScope in lesion margin delineation.
Of the 13 studies on lesion diagnosis, six used VivaScope 1500 and one used VivaScope 1500 or 3000.
For earlier versions of VivaScope, three studies used VivaScope 1000, and two studies used both VivaScope
1000 and VivaScope 1500. Only one study used VivaScope 2500.
The majority of the 16 included studies had a low risk of bias and low applicability concerns in patient
selection, conduct of the index test and reference standard. However, concerning flow and timing, the risk
of bias in the majority of the studies was unclear because of poor reporting and/or insufficient data.
The included studies were heterogeneous in terms of study design (e.g. RCM alone or RCM after
dermoscopy), patient population (e.g. different prior history of melanoma) or reporting of results
(e.g. patient based or lesion based). Thus, it was considered unfeasible to combined their results in a
meta-analysis.
Diagnostic accuracy
Diagnostic accuracy was the most commonly reported outcome, reported as sensitivity, specificity, positive
predictive value or negative predictive value. Other diagnostic accuracy data, such as FP, FN and true
negative (TN) rates, were rarely reported and had to be estimated/calculated using other reported
diagnostic data where possible.
Two studies that investigated the use of VivaScope for lesion diagnosis were deemed to be the most
representative of clinical practice in the UK setting. These were validated by clinical experts and, therefore,
formed the basis of the health economic analysis for diagnosis of malignant melanoma.
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One of the two studies assessed the impact of VivaScope 1500 on dermoscopically equivocal lesions.
Of the 343 lesions subjected to VivaScope examination, only 264 were excised (the remaining 79 lesions
were followed up for 1 year but no melanoma was diagnosed). Based on the 264 excised lesions,
dermoscopy plus VivaScope 1500 was significantly more sensitive than dermoscopy alone in the diagnosis
of melanoma (97.8% vs. 94.6%; p= 0.043) and significantly more specific than dermoscopy alone in the
diagnosis of non-melanoma (92.4% vs. 26.74%; p< 0.000001). Alternatively, assuming that the 79
lesions followed up were TNs, the sensitivities (RCM 97.8% vs. dermoscopy 93.5%) were similar, while the
specificity for VivaScope was higher (RCM 94.8% vs. dermoscopy 49.0%).
The second study prospectively assessed the potential impact of VivaScope 1500 in a routine melanoma
workflow. At the dermoscopy, patients were referred to one of the following pathways:
l no further examination
l referral to RCM
¢ RCM documentation (lesions with consistent suspicious clinical/dermoscopic criteria, already
qualified and scheduled for surgical excision)
¢ RCM consultation (equivocal, or moderately suspicious, lesions in which RCM diagnosis would
determine the lesion-definite outcome, i.e. either excision or digital follow-up).
Of 491 lesions, 183 were referred for RCM documentation and 308 for RCM consultation. In the RCM
documentation group, histopathology confirmed 110 RCM positives (23 melanomas, 19 BCCs and
68 benign lesions) and 73 RCM negatives (73 benign lesions).
In the RCM consultation group, RCM identified 81 positives (lesions diagnosed by RCM to be malignant)
and 227 negatives (lesions diagnosed by RCM to be non-malignant). Of the 81 RCM positives, excision
confirmed six melanomas, 19 BCCs and 56 benign lesions. Of the 227 RCM negatives followed up for
3–12 months, 28 showed significant changes but excision confirmed no malignancy, 178 showed no
changes and 21 were lost to follow-up but checks at the local tumour registry identified no excision.
Based on the assumption that all the 21 RCM negatives lost to follow-up in the RCM consultation group
were TNs, the sensitivity (RCM documentation 100% vs. RCM consultation 100%) and specificity (RCM
documentation 51.77% vs. RCM consultation 78.6%) were calculated. However, when the 21 RCM
negatives lost to follow-up were excluded, the sensitivity was 100% and specificity was 80.2% for
RCM consultation.
One study that investigated the use of VivaScope 1500 in margin delineation was also deemed to be the
most representative of clinical practice in the UK setting. Our clinical experts validated this and this trial
formed the basis for the health economic analysis of VivaScope-assisted margin delineation.
This study analysed LM and LM melanoma (LMM) cases to determine whether or not VivaScope 1500
mapping might alter patient care and management. Out of 60 positive sites for LM confirmed by
histopathology, 55 (FN= 5) had been confirmed by VivaScope 1500 and 21 (FN= 39) by dermoscopy, and,
out of 125 LM sites confirmed as negative by histopathology, 121 (FP= 4) had been confirmed by
VivaScope 1500 and 122 (FP= 3) by dermoscopy. Histopathology also showed that 17 out of 29 patients
with visible lesions had evidence of subclinical > 5mm beyond the edge of the dermoscopically identified
margin. In addition, both the length and width of the dermoscopically visible area of the lesion were, on
average, 60% smaller than that determined by VivaScope 1500.
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Cost-effectiveness results
The systematic review on cost-effectiveness identified only one economic evaluation. The study estimated
the impact of VivaScope use on the number of benign lesions needed to excise a malignant melanoma.
The results indicated that VivaScope reduces the number needed to excise of skin lesions suspicious of
melanoma and results in cost savings to the hospital. As the study was conducted in Italy, its findings may
not be generalisable to the UK setting.
The results of primary economic modelling indicate that the cost-effectiveness of VivaScope in the
diagnostic assessment of suspected melanomas was affected by the diagnostic accuracy data utilised in the
model. Using the more ‘optimistic’ diagnostic data from Alarcon et al. (Alarcon I, Carrera C, Palou J,
Alos L, Malvehy J, Puig S, et al. Impact of in vivo reflectance confocal microscopy on the number needed to
treat melanoma in doubtful lesions. Br J Dermatol 2014;170:802–8) resulted in a deterministic incremental
cost-effectiveness ratio (ICER) of £8877 per QALY (£9362 per QALY in probabilistic analysis), while the ‘less
favourable’ diagnostic data from Pellacani et al. (Pellacani G, Pepe P, Casari A, Longo C. Reflectance
confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and
saves unnecessary excisions: a longitudinal prospective study. Br J Dermatol 2014;171:1044–51) resulted in
a deterministic ICER of £19,095 per QALY (£25,453 per QALY in probabilistic analysis). VivaScope was also
shown to be a dominant strategy when used for the diagnostic assessment of suspected BCCs with a
positive or equivocal finding on dermoscopy.
Regarding margin delineation of LM, mapping with VivaScope was shown to be cost-effective, as indicated
by a deterministic ICER of £10,241 per QALY (£11,651 per QALY in probabilistic analysis). When
VivaScope was used for diagnosis as well as mapping of LM, then the intervention cost was reduced and it
became a dominant strategy.
One-way sensitivity analysis showed that the most influential parameters across all models were those
relating to permanent disutility as a result of scarring following surgical intervention of skin lesions on the
head or neck (such as the percentage of people experiencing permanent disutility as well as the value of
disutility itself) and the disutility because of anxiety while waiting for the results of biopsy.
Conclusion
VivaScope subsequent to dermoscopy may improve the diagnostic accuracy of equivocal skin lesions
compared with dermoscopy alone, particularly for malignant melanomas. In terms of margin delineation,
VivaScope 1500 mapping for LM and LMM may improve the accuracy in terms of complete excision of
lesions compared with dermoscopically determined margins.
In addition, the use of VivaScope appears to be a cost-effective strategy in the diagnostic assessment
of suspected skin cancer (more specifically, of suspected melanomas with an equivocal finding on
dermoscopy and suspected BCCs with a positive or equivocal finding on dermoscopy) and the margin
delineation of LM prior to surgical treatment, in particular when VivaScope is used for all three indications
considered in the economic analysis.
Limitations
First, UK data are lacking in the included studies and, therefore, generalisability of the results to the UK
population is unclear. This has implications for the NHS.
Second, apart from diagnostic accuracy and lesion recurrence rate (only reported by one study), none of
the outcomes specified in the protocol was reported in the included studies.
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Third, none of the included studies reported diagnostic accuracy results of SCC with VivaScope. This
confirms evidence in the literature that suggest SCCs can be difficult to view using imaging techniques
because their upper surface is often scaly, which can make it difficult to view detail at sufficient resolution.
Fourth, in some of the studies, there was a paucity of data and/or low quality of reported data on the
number of patients with positive and negative test results, making it impossible to construct a 2 × 2
contingency table to calculate sensitivity and specificity.
Further research is also needed on the impact of diagnostic imaging systems on HRQoL in order to
determine the cost-effectiveness of alternative diagnostic strategies in this area with higher certainty.
Study registration
This study is registered as PROSPERO CRD42014014433.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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